Vaxcyte VAX-31 Phase 3 Trial Meets All Primary Endpoints
Vaxcyte reported positive topline Phase 3 OPUS-1 results for VAX-31, meeting all prespecified immunogenicity and safety endpoints versus PCV20/PCV21.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.